TOP > News Release > R&D
- Guide to Category Symbols
Corporate
R&D
Products
Others
2008
-
- Luitpold Pharmaceutical's INJECTAFER(TM)
(ferric carboxymaltose injection) receives non-approvable letter from FDA - Luitpold Pharmaceutical's INJECTAFER(TM)
-
- FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel
Investigational antiplatelet agent submitted for treatment of patients with acute coronary syndrome being managed with percutaneous coronary intervention - FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel
-
- Daiichi Sankyo, Lilly Submit Marketing Authorization Application for
Investigational Oral Antiplatelet Drug, Prasugrel, to European
Medicines Agency - Daiichi Sankyo, Lilly Submit Marketing Authorization Application for
-
- FDA Advisory Committee Supports Favorable Risk-Benefit Profile for Injectafer(TM)(Ferric Carboxymaltose Injection) Under Certain Indications for Use
-
- Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
-
- Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet
Drug, Prasugrel, with U.S. Food and Drug Administration
If Approved for Marketing in the United States, Trade Name Will be Effient(TM) - Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet
2007
-
- In Landmark Phase III Head-to-Head Study, Prasugrel Statistically
Superior to Clopidogrel in Reducing Risk of Heart Attack
- In Landmark Phase III Head-to-Head Study, Prasugrel Statistically
-
- Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
-
- DAIICHI SANKYO EUROPE is applying for approval of its new
combination product of Olmesartan and Amlodipin - DAIICHI SANKYO EUROPE is applying for approval of its new
-
- Enrollment Completed in Pivotal Phase III Study Comparing Prasugrel to Clopidogrel in Patients with Acute Coronary Syndrome
2006
-
- New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses
-
- The Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug
Loxonin Poultice 100mg Receives Approval for Manufacture - The Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug
2005
-
- Joint Research in Genome-based Target Discovery between Daiichi Pharmaceutical Co., Ltd. and Celestar Lexico-Sciences, Inc. has concluded
-
- Large Scale Clinical Trial MEGA Study* Employing the Hyperlipidemia Drug Mevalotin®
-
- Discontinuation of Clinical Studies of CS-505
(Pactimibe; Sankyo's ACAT Inhibitor) - Discontinuation of Clinical Studies of CS-505
-
- Completion of the Registration of Trial Subjects for ORIENT on the Suppressive Effects of the Angiotensin II Receptor Blocker Olmetec® against the Progression of Diabetic Nephropathy
